Abstract
Bendamustine demonstrated clinical activity in pre-treated hematological malignancies due to its unique mechanism of action distinct from standard alkylating agents. This study assessed its efficacy in patients with chronic lymphocytic leukemia pre-treated with an alkylator, in comparison to fludarabine. Patients with relapsed chronic lymphocytic leukemia requiring treatment after one previous systemic regimen (usually chlorambucil-based) were randomized to either receive bendamustine 100 mg/m2 on days 1 and 2 of a 4-week cycle or standard fludarabine treatment consisting of 25 mg/m2 on days 1 to 5 every 4 weeks. The primary objective was to achieve non-inferior progression-free survival (PFS) with bendamustine. Out of a total of 96 patients randomized, 92 were eligible, 49 allocated to bendamustine and 43 to fludarabine. About half of the patients received six or more cycles. Overall response rates were 76 % on bendamustine and 62 % on fludarabine, with clinical complete response rates of 27 and 9 %, respectively. Median PFS was 20.1 and 14.8 months (hazard ratio, 0.87; 90 % confidence interval, 0.60–1.27), median overall survival 43.8 and 41.0 months (hazard ratio, 0.82). Thrombocytopenia and gastrointestinal toxicities were marginally more frequent on bendamustine, albeit CTC grade 3/4 event incidence was similar. These data suggest at least comparable efficacy of bendamustine vs. fludarabine, pointing to an alternative treatment option in relapsing CLL patients after chlorambucil containing initial chemotherapy.
Similar content being viewed by others
References
Kalil N, Cheson BD (1999) Chronic lymphocytic leukemia. Oncologist 4:352–369
Hallek M, Fischer K, Fingerle-Rowson G et al (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376:1164–1174
Tam CS, O’Brien S, Wierda W et al (2008) Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood 112:975–980
Cheson BD, Rummel MJ (2009) Bendamustine: rebirth of an old drug. J Clin Oncol 27:1492–1501
Gandhi V (2002) Metabolism and mechanism of action of bendamustine: rationales for combination therapies. Semin Oncol 29(suppl 13):4–11
Leoni LM, Bailey B, Reifert J et al (2008) Bendamustine (Treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agents. Clin Cancer Res 14:309–317
Balfour JAB, Goa KL (2001) Bendamustine. Drugs 61:631–638
Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin’s lymphomas. Anti-Cancer Drugs 12:725–729
Rummel MJ (2008) Bendamustine in chronic lymphocytic leukemia and refractory lymphoma. Semin Hematol 45(suppl 2):S7–S10
Knauf W (2009) Bendamustine in the treatment of chronic lymphocytic leukemia. Expert Rev Anticancer Ther 9:165–174
Cheson BD, Bennett JM, Rai KR et al (1996) National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 87:4990–4997
Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Ass 53:457–481
Peto R, Peto J (1972) Asymptotically efficient rank invariation test procedures (with discussion). J R Stat Soc A 135:185–206
Johnson S, Smith AG et al (1996) Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia: French Cooperative Group on CLL. Lancet 347:1432–1438
Keating MJ, O’Brien S, Kantarjian H et al (1993) Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as single agent. Blood 81:2878–2884
Kath R, Blumenstengel K, Fricke HJ et al (2001) Bendamustine monotherapy in advanced and refractory chronic lymphocytic leukemia. J Cancer Res Clin Oncol 127:48–54
Aivado M, Schulte K, Henze L et al (2002) Bendamustine in the treatment of chronic lymphocytic leukamia: results and future perspectives. Semin Oncol 29(suppl 13):19–22
Bremer K (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pretreated low-grade non-Hodgkin’s lymphomas. J Cancer Res Clin Oncol 128:603–609
Bergmann MA, Goebeler ME, Herold M et al (2005) Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group. Haematologica 90:1357–1364
Lissitchkov T, Arnaudov G, Peytchev D et al (2006) Phase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCL in pre-treated patients with B-chronic lymphocytic leukaemia (Binet stages B and C) requiring therapy. J Cancer Res Clin Oncol 132:99–104
Fischer K, Cramer P, Busch R et al (2011) Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol 29:3559–3566
Köppler H, Heymanns J, Pandorf A, Weide R (2004) Bendamustine plus mitoxantrone—a new effective treatment for advanced chronic lymphocytic leukaemia: results of a phase I/II study. Leuk Lymphoma 45:911–913
Weide R, Pandorf A, Heymanns J et al (2004) Bendamustine/mitoxantrone/rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies—final report of a pilot study. Leuk Lymphoma 45:2445–2449
Steurer M, Schmidt S (2009) Chronic lymphocytic leukaemia: an update. Memo 2:142–145
Knauf WU, Lissichkov T, Aldaoud A et al (2009) Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia. J Clin Oncol 27:4378–4384
Funding
This work was supported in part by unrestricted research grants from Mundipharma GmbH, Germany, and Ribosepharm GmbH, Germany.
Conflict of interest
Norbert Niederle received honoraria from Mundipharma GmbH; Wolfgang Knauf advised and received honoraria from Mundipharma GmbH; the remaining authors declare no competing financial interests.
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented in abstract form at the 15th Congress of the European CanCer Organisation and 34th Congress of the European Society for Medical Oncology, Berlin, Germany, September 20–24, 2009.
Rights and permissions
About this article
Cite this article
Niederle, N., Megdenberg, D., Balleisen, L. et al. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia. Ann Hematol 92, 653–660 (2013). https://doi.org/10.1007/s00277-012-1660-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-012-1660-6